secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061519
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena reports Q3 cash $196.9M, IK-930 shows stable disease in all 7 EHE patients
--------------------------------------------------------------------------------

- Q3 2023 cash, cash equivalents and marketable securities of $196.9M; runway into 2026.
- IK-930 dose escalation: 26 patients treated; 7/7 EHE patients achieved stable disease, 3 with tumor shrinkage.
- Treatment-related proteinuria in 3/26 patients, all grade 1-2, no dose reductions or interruptions.
- IK-595 clinical trial expected to initiate by end of 2023; IK-930 data update planned for H2 2024.
- Collaboration revenue $1.2M vs $6.4M YoY; R&D expenses $14.7M vs $18.9M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000095017023061519/0000950170-23-061519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000095017023061519/ikna-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer